Clinical trials: Psychological Disorders
Depressive Disorder, Depression
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
To compare the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy to an assigned open label antidepressant therapy (ADT) in the proposed subject population with MDD.
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- NCT01727726
- Testing
- Brexpiprazole, Seroquel XR
- Where
- 76 sites in United States, Canada and 5 more
- Volunteers
- 2,182 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Weight Gain, Sialorrhea
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or…
- Trial name
- FOCUS (NCT00683891)
- Testing
- FazaClo (clozapine, USP) ODT
- Where
- 2 sites in United States
- Sponsor
- Azur Pharma, Inc
Schizophrenia
A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia
The purpose of this study is to evaluate the long term safety of flexible doses (50 to 150 mg equivalent) of paliperidone palmitate in the treatment of patients with schizophrenia and to document the pharmacokinetics of…
- Trial name
- NCT01150448
- Testing
- Paliperidone palmitate Treatment A, Paliperidone palmitate Treatment B
- Where
- 28 sites in United States, Belgium and 8 more
- Volunteers
- 212 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Autistic Disorder
An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)
The primary study objective is to evaluate the efficacy of Vayarin_005 on ASD related symptoms in children.
- Trial name
- NCT02222285
- Testing
- Medical Food : Vayarin_005
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Enzymotec
Healthy Volunteer, Autistic Disorder, Asperger's Syndrome
A Non-Drug Study on the Relationship Between Exploratory Biomarkers and Functional Dimensions in Individuals With Autistic Disorder or Asperger's Syndrome
This multi-center, non-drug study will explore the relationship between exploratory biomarkers and functional dimensions in male adult individuals with Autistic Disorder or Asperger's Syndrome and healthy volunteer controls.
- Trial name
- NCT01669889
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease
A 6-month randomized, double-blind and placebo-controlled, followed by a 6-month open label extension study.
- Trial name
- NCT02991235
- Testing
- PRJ212
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Bioiberica
Anxiety
Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder
The purpose of the study is to compare pregabalin to Venlafaxine XR and placebo in the treatment of generalized anxiety disorder.
- Trial name
- NCT00151450
- Testing
- Pregabalin, Venlafaxine XR
- Where
- 45 sites in Belgium, Canada and 6 more
- Volunteers
- 390 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Diabetes Mellitus
A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess and compare how risperidone and olanzapine, two antipsychotic medications, affect the regulation of glucose (sugar) in the body.
- Trial name
- NCT00236379
- Testing
- Olanzapine, Risperidone
- Volunteers
- 59 people
- Sponsor
- Janssen, LP
Huntington's Disease, Chorea
Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea
This study will assess the efficacy, safety and tolerability of AFQ056 when added to optimize standard therapy in patients that have Huntington's disease in reducing chorea.
- Trial name
- NCT01019473
- Testing
- AFQ056
- Where
- 10 sites in Germany, United Kingdom
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer´s Disease
To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease
The purpose of this study is to evaluate whether treatment with single and multiple oral doses of AZD1446 for 1 week will have effect on Quantified Electroencephalography and Event-Related Potentials in patients with Alzheimers…
- Trial name
- NCT01125683
- Testing
- AZD1446, Donepezil
- Where
- 7 sites in Russia, Ukraine
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Opioid Dependence, on Agonist Therapy
Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
The purpose of this study was to assess safety, efficacy, and treatment retention following extended treatment with OX219, a higher-bioavailability buprenorphine/naloxone (BNX) sublingual tablet formulation in opioid-dependent…
- Trial name
- NCT01903005
- Testing
- Higher bioavailability BNX sublingual tablets
- Where
- 28 sites in United States
- Volunteers
- 668 people
- Sponsor
- Orexo AB
Restless Legs Syndrome
A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS
The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with placebo on periodic leg movements (PLMS) arousl index and sleep efficiency in patients with RLS.
- Trial name
- NCT00627003
- Testing
- Cabergoline
- Volunteers
- 43 people
- Sponsor
- Pfizer
Schizophrenia
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
- Trial name
- NCT00080327
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 370 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00257673
- Testing
- MEM 1003
- Where
- 57 sites in United States
- Volunteers
- 183 people
- Sponsor
- Memory Pharmaceuticals
Major Depressive Disorder, Major Depressive Episode
Mobile Observation Of Depression
The primary aim of this project is to test if OCOsense glasses can function as a digital phenotyping tool derived from behavioural and physiological signals related to facial expression and motion recorded using the glasses.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Bipolar Disorder
- Trial name
- MOOD (NCT05815459)
- Testing
- OCOsense
- Where
- United Kingdom
- Volunteers
- 84 people
- Sponsor
- Emteq Ltd
Alzheimer's Disease
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients
The main purpose of this study is to evaluate the cognitive changes after administration of tideglusib versus placebo at two oral doses and two treatment regimes for 26 weeks in patients with mild to moderate Alzheimer's disease.
- Trial name
- ARGO (NCT01350362)
- Testing
- tideglusib
- Where
- 6 sites in Belgium, Finland and 4 more
- Volunteers
- 306 people
- Sponsor
- Noscira SA
Gastrointestinal Dysfunction, Malnutrition
Postoperative GI Dysfunction and Nutrition in Malnourished Cancer Surgery Patients
This is a prospective two-center observational cohort study in adult patients undergoing major abdominal and/or pelvic oncologic surgery with pre-existing malnutrition.
- Conditions
- Gastrointestinal Dysfunction, Malnutrition, Delirium - Postoperative, Abdominal Neoplasm
- Trial name
- GIDNUT (NCT07622888)
- Testing
- Serotonin (e.g., serotonin adipinate), Standard Prokinetic Therapy (excluding serotonin)
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Arma Ltd.
Schizophrenia
Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission
The purpose of this study is to investigate the safety and efficacy of flexibly dosed paliperidone extended-release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Trial name
- PERFECT (NCT00761579)
- Testing
- Paliperidone
- Where
- 8 sites in South Korea
- Volunteers
- 190 people
- Sponsor
- Janssen Korea, Ltd., Korea
Bipolar Disorder
BIMET Study: Evolution of Metabolic and Cardiovascular Risks Factors in Patients With Bipolar Disorder
To assess the prevalence of Metabolic Syndrome in Spanish population with Bipolar I or II Disorder. To analyse the clinical progress disease in patients with Bipolar I or II Disorder for 12 months using the assessment of the…
- Trial name
- BIMET (NCT00584961)
- Testing
- non-interventional
- Volunteers
- 553 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cognitive Impairment, Memory Complaint
Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients…
- Conditions
- Cognitive Impairment, Memory Complaint, Clinical Investigation in Memory Centers
- Trial name
- DIALOG (NCT02221661)
- Volunteers
- 606 people
- Sponsor
- Diaxonhit
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.